FY2027 Earnings Forecast for CRSP Issued By Zacks Research

CRISPR Therapeutics AG (NASDAQ:CRSP) – Analysts at Zacks Research issued their FY2027 earnings per share estimates for shares of CRISPR Therapeutics in a report released on Tuesday, March 4th. Zacks Research analyst R. Department anticipates that the company will earn ($4.62) per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

CRSP has been the subject of a number of other reports. The Goldman Sachs Group decreased their target price on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research report on Friday, February 14th. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. HC Wainwright reissued a “buy” rating and set a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Finally, Chardan Capital lowered their price target on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, CRISPR Therapeutics presently has an average rating of “Hold” and a consensus price target of $74.40.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $43.45 on Wednesday. The firm has a market capitalization of $3.73 billion, a PE ratio of -9.94 and a beta of 1.67. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $83.50. The company has a 50-day simple moving average of $42.57 and a 200-day simple moving average of $45.86.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, Director John Greene purchased 7,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 26th. The stock was purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the transaction, the director now directly owns 7,000 shares of the company’s stock, valued at approximately $313,950. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Samarth Kulkarni sold 18,360 shares of the firm’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the transaction, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This trade represents a 9.66 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Institutional investors have recently bought and sold shares of the business. Boston Family Office LLC increased its stake in CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares in the last quarter. Bedell Frazier Investment Counselling LLC grew its holdings in shares of CRISPR Therapeutics by 0.8% in the 3rd quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after buying an additional 218 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of CRISPR Therapeutics by 1.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after buying an additional 231 shares in the last quarter. Intellectus Partners LLC raised its stake in CRISPR Therapeutics by 3.6% during the 4th quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock worth $281,000 after buying an additional 250 shares during the period. Finally, Farrow Financial Inc. lifted its holdings in CRISPR Therapeutics by 1.4% during the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock worth $777,000 after acquiring an additional 270 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.